Drugs / NGP 555
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02537938 | Jan → Dec 2016 | Alzheimer disease | NeuroGenetic Pharmaceuticals Inc | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02534480 Comparator | Mar → Oct 2015 | Alzheimer disease | NeuroGenetic Pharmaceuticals Inc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NGP 555 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02537938 ↗ |
| Modality | Small molecule | “NGP 555 is a small molecule preventative therapy” NCT02534480 ↗ |
| Route | Oral | “by mouth” NCT02534480 ↗ |